Skip to main content
Signal8

Full Access with Signal8 Pro, $49/mo billed annually.

ASTRAZENECA PLC (AZN) Form 6-K — Sep 1, 2026

$AZNForm 6-KFiled Sep 1, 2026, 7:18 AM ET0001654954-26-007988Original filing

AstraZeneca PLC announced on 1 September 2026 that Wan Ling Martello has been appointed as a Non-Executive Director with immediate effect, joining the Board's Audit Committee on appointment. Martello is a former Nestlé global CFO who later led Nestlé's Asia, Oceania and Sub-Saharan Africa business, and currently serves as a founding partner of Boston-based private equity firm BayPine, an Independent Director of Alibaba Group, and a Director of The Lovesac Company, with prior board seats at Uber Technologies and Stellantis. AstraZeneca Chair Michel Demaré said her CFO and digital transformation experience will significantly benefit her Audit Committee work.

Key figures

Prior Board Uber
June 2017 to May 2025
Joins Audit Committee
Yes
Prior Board Stellantis
January 2021 to April 2025
Appointment Effective Date
1 September 2026

AI analysis

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.